Moreover, we observed that myeloid TREM1 frequency also associated with clinical breast cancer subtype (TNBC, ER+, HER2+), whereby an overall difference in rank of the percentage of TREM1-expressing cells was significant (P=0.03, three-group Kruskal-Wallis test). This evidence concerns the gene ERBB2 and breast cancer.